Bevacizumab

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (13:18, 9 January 2024) (edit) (undo)
 
(9 intermediate revisions not shown.)
Line 1: Line 1:
-
<applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Bevacizumab, also known as Avastin"/>
+
<StructureSection load='' size='350' side='right' scene='Bevacizumab/Ba/1' caption='Model Bevacizumab, also known as Avastin (PDB code [[1igt]])'>
 +
__TOC__
 +
 
===Better Known as: Avastin===
===Better Known as: Avastin===
* Marketed By: Genentech & Roche<br />
* Marketed By: Genentech & Roche<br />
* Major Indication: Colorectal [[Cancer]]<br />
* Major Indication: Colorectal [[Cancer]]<br />
-
* Drug Class: [[VEGF]] Inhibitor - [[Monoclonal Antibody]]
+
* Drug Class: [[Vascular Endothelial Growth Factor]] Inhibitor - [[Monoclonal Antibody]]
-
* Date of FDA Approval (Patent Expiration): 2004 (
+
* Date of FDA Approval (Patent Expiration): 2004 (2019)
-
* 2009 Sales: $4.8 Billion<ref>Irena Melnikova, Therapies for Alzheimer's disease, Nature Reviews Drug Discovery 6, 341-342 (May 2007)</ref>
+
* 2009 Sales: $4.8 Billion
* Importance: It is one of the best selling [[cancer]] treatments in history. Despite being effective against colorectal cancer, post-approval studies after accelerated approval revealed that Avastin was ineffective in treating breast cancer. Many question the $90,000/year bill to take Avastin when it extends life on average only 10 months.
* Importance: It is one of the best selling [[cancer]] treatments in history. Despite being effective against colorectal cancer, post-approval studies after accelerated approval revealed that Avastin was ineffective in treating breast cancer. Many question the $90,000/year bill to take Avastin when it extends life on average only 10 months.
-
* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information
+
* See [[Pharmaceutical Drugs]] for more information about other drugs and disorders
===Mechanism of Action===
===Mechanism of Action===
 +
[[Vascular Endothelial Growth Factor]] (VEGF) is a signal protein often over-expressed in cancerous cells. It is responsible for activating [[Vascular Endothelial Growth Factor Receptors]] (VEGFRs) to accelerate angiogenesis and vasculogenesis. Accelerated angiogenesis creates the overly developed blood vessel system common to all tumors, providing oxygen and nutrients to the prodigal tumors. Bevacizumab binds to VEGF, preventing it from interacting with VEGFR, thus halting accelerated angiogenesis in tumors, preventing the cancer from growing rapidly.<ref>PMID:11815711</ref>
===Pharmacokinetics===
===Pharmacokinetics===
{| class="wikitable" border="1" width="30%" style="text-align:center"
{| class="wikitable" border="1" width="30%" style="text-align:center"
|-
|-
-
! colspan="2" align="center"| VEGF Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]<ref>PMID:17093010</ref>
+
! colspan="2" align="center"| VEGF Inhibitor [[Pharmacokinetics]]<ref>PMID:17093010</ref>
|-
|-
! Parameter
! Parameter
! [[Bevacizumab]]
! [[Bevacizumab]]
|-
|-
-
! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr)
+
! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr)
! 5.17
! 5.17
|-
|-
-
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)
+
! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml)
! 284000
! 284000
|-
|-
-
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)
+
! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
! 100
! 100
|-
|-
-
! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (days)
+
! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (days)
! 20
! 20
|-
|-
-
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ug/ml/hr)
+
! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ug/ml/hr)
! 97488
! 97488
|-
|-
-
! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM)
+
! [[Pharmacokinetics#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM)
! .9
! .9
|-
|-
-
! [[Pharmaceutical_Drugs#Clearance_.28Cl.29|Clearance]] (L/h)
+
! [[Pharmacokinetics#Clearance_.28Cl.29|Clearance]] (L/h)
! .0096
! .0096
|-
|-
Line 43: Line 46:
! 10
! 10
|}
|}
-
 
+
</StructureSection>
-
 
+
===References===
===References===
<references/>
<references/>
__NOEDITSECTION__
__NOEDITSECTION__
__NOTOC__
__NOTOC__

Current revision

Model Bevacizumab, also known as Avastin (PDB code 1igt)

Drag the structure with the mouse to rotate

References

  1. ↑ Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. 2001;106(4):148-56. PMID:11815711
  2. ↑ Garnier-Viougeat N, Rixe O, Paintaud G, Ternant D, Degenne D, Mouawad R, Deray G, Izzedine H. Pharmacokinetics of bevacizumab in haemodialysis. Nephrol Dial Transplant. 2007 Mar;22(3):975. Epub 2006 Nov 8. PMID:17093010 doi:10.1093/ndt/gfl664


Proteopedia Page Contributors and Editors (what is this?)

David Canner, Michal Harel, Joel L. Sussman, Alexander Berchansky

Retrieved from "http://52.214.119.220/wiki/index.php/Bevacizumab"
Personal tools